Literature DB >> 19073420

Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.

Richard M Kostrzewa1, John P Kostrzewa, Russell W Brown, Przemyslaw Nowak, Ryszard Brus.   

Abstract

The process of receptor supersensitivity (RSS) has a long history and is an epiphenomenon of neuronal denervation. Dopamine (DA) RSS (DARSS) similarly occurs after DA denervation, and this process is invoked in neuropsychiatric and neurodegenerative disorders. From studies largely over the past 25 years, much has been learned regarding DARSS. For example, overt D1 DARSS occurs after perinatal destruction of nigrostriatal DA fibers. However, following perinatal destruction of DA innervation, the most-prominent behavioral effects of a D1 agonist are observed after a series of D1 agonist treatments--a process known as priming of D1 DA receptors. Moreover, perinatal lesioning of DA fibers produces prominent serotonin (5-HT) RSS, and in fact 5-HT RSS appears to modulate D1 DA RSS. In rodents, receptor supersensitization by these means appears to be irreversible. In contrast to the observed D1 DARSS, D2 DARSS apparently does not occur after perinatal DA denervation. Also, while repeated D1 agonist treatment of intact rats has no observable effect, repeated D2 agonist treatments, during or after the ontogenetic phase, produces prominent life-long D2 RSS. The process may have an association with substance abuse. Therefore, production of D1 and D2 DARSS occurs by different means and under different circumstances, and in association with perhaps different neuronal phenotypes, and with greater incidence in either intact (D2) or DA-lesioned counterparts (D1). The physiological consequence of RSS are multiple.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073420     DOI: 10.1007/BF03033804

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  62 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA.

Authors:  R M Kostrzewa; L Gong
Journal:  Pharmacol Biochem Behav       Date:  1991-07       Impact factor: 3.533

3.  Induction of oral dyskinesias in naive rats by D1 stimulation.

Authors:  H Rosengarten; J W Schweitzer; A J Friedhoff
Journal:  Life Sci       Date:  1983-12-19       Impact factor: 5.037

Review 4.  A dopamine deficiency model of Lesch-Nyhan disease--the neonatal-6-OHDA-lesioned rat.

Authors:  G R Breese; H E Criswell; G E Duncan; R A Mueller
Journal:  Brain Res Bull       Date:  1990-09       Impact factor: 4.077

5.  Elevation of dopamine D2 but not D1 receptors in adult rat neostriatum after neonatal 6-hydroxydopamine denervation.

Authors:  K M Dewar; J J Soghomonian; J P Bruno; L Descarries; T A Reader
Journal:  Brain Res       Date:  1990-12-17       Impact factor: 3.252

6.  Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats.

Authors:  L Gong; R M Kostrzewa; R Brus; R W Fuller; K W Perry
Journal:  Brain Res Dev Brain Res       Date:  1993-11-19

7.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

8.  Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats.

Authors:  T W Berger; S Kaul; E M Stricker; M J Zigmond
Journal:  Brain Res       Date:  1985-06-17       Impact factor: 3.252

9.  Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.

Authors:  G R Breese; A Baumeister; T C Napier; G D Frye; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1985-11       Impact factor: 4.030

10.  Ontogenetic quinpirole treatment induces vertical jumping activity in rats.

Authors:  R M Kostrzewa; J Guo; F P Kostrzewa
Journal:  Eur J Pharmacol       Date:  1993-08-03       Impact factor: 4.432

View more
  16 in total

Review 1.  Stereotypic progressions in psychotic behavior.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Rose Anna Kostrzewa; Florence P Kostrzewa; Ryszard Brus; Przemyslaw Nowak
Journal:  Neurotox Res       Date:  2010-04-22       Impact factor: 3.911

Review 2.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

3.  Behavioral effects of dopamine receptor inactivation in the caudate-putamen of preweanling rats: role of the D2 receptor.

Authors:  Taleen Der-Ghazarian; Crystal B Widarma; Arnold Gutierrez; Leslie R Amodeo; Joseph M Valentine; Danielle E Humphrey; Ashley E Gonzalez; Cynthia A Crawford; Sanders A McDougall
Journal:  Psychopharmacology (Berl)       Date:  2013-09-22       Impact factor: 4.530

4.  p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease.

Authors:  John P Kostrzewa; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2020-01-14       Impact factor: 3.911

Review 5.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

Review 6.  Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders.

Authors:  Richard M Kostrzewa; Karolina Wydra; Malgorzata Filip; Cynthia A Crawford; Sanders A McDougall; Russell W Brown; Dasiel O Borroto-Escuela; Kjell Fuxe; Raul R Gainetdinov
Journal:  J Pharmacol Exp Ther       Date:  2018-06-19       Impact factor: 4.030

7.  Neonatal 6-hydroxydopamine lesioning enhances quinpirole-induced vertical jumping in rats that were quinpirole primed during postnatal ontogeny.

Authors:  Richard M Kostrzewa; Florence P Kostrzewa
Journal:  Neurotox Res       Date:  2011-08-19       Impact factor: 3.911

8.  Chemoattractant-induced signaling via the Ras-ERK and PI3K-Akt networks, along with leukotriene C4 release, is dependent on the tyrosine kinase Lyn in IL-5- and IL-3-primed human blood eosinophils.

Authors:  Yiming Zhu; Paul J Bertics
Journal:  J Immunol       Date:  2010-11-24       Impact factor: 5.422

Review 9.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

10.  Staging neurological disorders: expressions of cognitive and motor disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2009-11-26       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.